---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-001277"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2026-09-23T20:11:34+00:00"
generated_at: "2026-09-23T20:13:09.709771+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcturus reports positive ARCT-810 Phase 2 data, unveils LUNAR 2.0 platform, to acquire myNEO

## Summary
- ARCT-810 generally safe; reduced/maintained fasting ammonia and glutamine in OTC deficiency patients.
- LUNAR 2.0 shows 40-fold higher hEPO and 38-fold higher hOTC expression vs LUNAR 1.0 in NHP studies.
- FDA feedback supports ARCT-2601 integration into ongoing Phase 2 study by year-end 2026.
- Definitive agreement to acquire myNEO; closing expected in October 2026.
- New programs for PKU and Gout announced using LUNAR 2.0.

## SEC filing metadata
- accession: 0001193805-26-001277
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2026-09-23T20:11:34+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380526001277/0001193805-26-001277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380526001277/e665798_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-001277
- JSON: https://secwatch.observer/filing/0001193805-26-001277.json
- Plain text: https://secwatch.observer/filing/0001193805-26-001277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.